Overview
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Eligibility
Inclusion Criteria:
- Diagnosis of Multiple sclerosis (MS)
- Currently or recently pregnant
- Reside in a country where ozanimod is prescribed for treatment of MS
Exclusion Criteria:
- Diagnostic prenatal test results known prior to first contact with the Registry Coordination Center (RCC)
- Exposure to known teratogens and/or investigational medications during pregnancy
Other protocol-defined inclusion/exclusion criteria apply